SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dell Technologies, Inc. is a technology company, providing customers with a broad and innovative solution portfolio to help customers modernize their information technology (IT) infrastructure, address workforce transformation, and offer critical solutions that keep people and organizations connected. It operates through the following segments: Infrastructure Solutions Group (ISG) and Client Solutions Group (CSG). The ISG segment includes servers, networking, and storage, as well as services and third-party software and peripherals that are closely tied to the sale of ISG hardware. The CSG segment includes designs for commercial and consumer customers of desktops, thin client products, and notebooks. The company was founded by Michael Saul Dell in 1984 and is headquartered in Round Rock, TX.

Dell Technologies Inc - Ordinary Shares - Class C

Dell Technologies Inc

Barclays downgrade of Dell and doubts about a meaningful enterprise AI spending acceleration have weighed on shares after a sharp run-up; the firm argues rising memory costs may be boosting reported revenue more than unit demand. Traders are divided, with bears focused on valuation and margin risks while bulls point to strong AI-server demand and backlog, and many call the selloff an overreaction.

United Parcel Service, Inc. is a package delivery company, which engages in the provision of global supply chain management solutions. It operates through the following segments: U.S. Domestic Package and International Package. The U.S. Domestic Package segment includes time-definite delivery of letters, documents, and packages. The International Package segment focuses on delivery and shipments in Europe, Asia, the Indian sub-continent, the Middle East, Africa, Canada, and Latin America. The company was founded by James E. Casey and Claude Ryan on August 28, 1907 and is headquartered in Atlanta, GA.

United Parcel Service, Inc. - Ordinary Shares - Class B

United Parcel Service, Inc.

Amazons launch of Supply Chain Services is driving concern that it could take business from UPS and intensify competition in shipping and logistics. Traders are split between viewing the selloff as an overreaction and fearing Amazons scale and pricing could pressure UPSs volumes and margins.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BCRX is drawing attention amid a steep share-price slide, with traders focused on Pharvaris as a potential HAE competitor and reports of an RBC downgrade citing a challenging near-term outlook. Bears worry about pressure on Orladeyo and execution risks around the Astria acquisition and Navenibart, while bulls argue the pediatric launch and continued Orladeyo growth could offset competition.

Arista Networks, Inc. engages in the development, marketing, and sale of cloud networking solutions. Its solutions include EOS, a set of network applications, and Gigabit Ethernet switching and routing platforms. Its product categories include core, cognitive adjacencies, and cognitive networks. The company was founded by Andreas Bechtolsheim, David Cheriton, and Kenneth Duda in November 2004 and is headquartered in Santa Clara, CA.

Arista Networks Inc

A sharp, high-volume pullback has traders debating whether ANET is in a broader tech and AI-infrastructure correction, with some also pointing to reported insider selling and concerns about the durability of AI spending. Others view the decline as overdone and are buying the dip, citing Aristas role in AI data-center networking and its strong fundamentals.

Adobe, Inc. is a global technology company, which engages in the provision of digital marketing and media solutions. It operates through the following segments: Digital Media, Digital Experience, and Publishing and Advertising. The Digital Media segment offers products and services that enable individuals, teams, businesses, and enterprises to create, publish, and promote content anywhere and accelerate productivity by transforming view, share, engage with and collaborate on documents and creative content. The Digital Experience segment focuses on integrated platform and set of products, services, and solutions that enable businesses to create, manage, execute, measure, monetize, and optimize customer experiences that span from analytics to commerce. The Publishing and Advertising segment includes legacy products and services that address diverse market opportunities, including eLearning solutions, technical document publishing, web conferencing, document and forms platform, web app development, high-end printing, and Adobe Advertising offerings. The company was founded by Charles M. Geschke and John E. Warnock in December 1982 and is headquartered in San Jose, CA.

Adobe Inc

Adobes shares are under pressure amid a Wells Fargo downgrade and concerns that AI-built, open-source clones such as ArtCraft could erode its creative-software moat and subscription growth. Traders disagree on the threats scale: bears see a risk to paid users and pricing power, while bulls argue the clones lack Adobes mature workflows, support, and enterprise ecosystem.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

Upcoming MSToronto presentations are driving attention, particularly initial Phase 1 azer-cel findings in progressive MS alongside BRIUMVI data on ENHANCE, long-term outcomes and subcutaneous dosing. Traders see the azer-cel readout as a potential upside catalyst, while some caution that early-stage data are preliminary and BRIUMVIs commercial growth remains the core thesis.

Planet Labs PBC provides daily data and insights about earth. It offers a web-geo platform with satellite data available and foundational analytics to derive insights to make decisions. The company is founded by William S. Marshall and Robert H. Schingler in 2010 and is headquartered in San Francisco, CA.

Planet Labs PBC - Ordinary Shares - Class A

Planet Labs PBC

Planet Labs is drawing attention amid a sharp selloff, with traders citing broader weakness in space stocks and concerns about dilution from the companys large at-the-market share program and its valuation. The community is split between investors buying the dip and bears who see further downside, while some attribute the decline to macro pressure rather than a company-specific setback.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

AXSM is drawing attention after a steep share-price decline as investors question whether Auvelitys launch for Alzheimers-related agitation is gaining traction quickly enough and whether MDD prescription growth is slowing. Traders disagree on whether reported prescription data undercounts demand because of sampling and long-term-care channels or reflects a genuinely slower rollout, with many looking to Q3 results and management for clarity.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom CEO Hock Tans remarks likening some AI investing to casino gambling and warning that capital could constrain the buildout have fueled concern about the sustainability of AI spending, alongside a broader semiconductor selloff. Traders disagree over whether the comments signal real risk or were taken out of context, with bulls pointing to continued AI demand and bears focused on financing and sentiment.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Anticipation is building around Iovances ESMO presentations on lifileucel in frontline melanoma and sarcoma, with traders also watching for a later NSCLC update and quarterly results. The recent selloff is often attributed to broader biotech weakness and profit-taking, though some debate whether the halted small pediatric trial contributed.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

A tiny GLP-1 implant is the latest bet to help patients maintain their weight loss

Vivani Medical is developing an implant of semaglutide, the active ingredient in Novo Nordisk's obesity injection Wegovy and diabetes counterpart Ozempic...

Vivani Scores Major Validation as Novo Nordisk Evaluates Its Ultra Long-Acting Semaglutide Platform

Vivani Medical (NASDAQ:VANI) has taken another step toward advancing its long-acting obesity treatment platform by entering into an agreement with Novo Nordisk, one of the global leaders in GLP-1 therapies. Under the agreement, Novo Nordisk will conduct a non-exclusive internal evaluation of Vivani's investigational semaglutide implant, NPM-139, highlighting growing industry interest in alternative drug delivery technologies for chronic weight management.

Why Did CLRO Stock Surge More Than 170% Today?

Equity

ClearOne is executing a reverse merger with a company developing brain implant devices.

ClearOne Announces Entry into Merger Agreement with Cortigent, Inc., a Wholly-Owned Subsidiary of Vivani Medical

ClearOne, Inc. (Nasdaq: CLRO) (ClearOne) announced today that it has entered into a definitive agreement and plan of merger (the Agreement) among its wholly-owned subsidiary (MergerSub), Vivani Medical, Inc. (Nasdaq: VANI; Vivani), and Cortigent, Inc. (Cortigent), a wholly-owned subsidiary of...

Vivani Medical (VANI) to Release Quarterly Earnings on Tuesday

Vivani Medical (NASDAQ:VANI) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at...

Vivani Medical (NASDAQ:VANI) Director Gregg Williams Purchases 1,587,301 Shares

Vivani Medical, Inc. (NASDAQ:VANI - Get Free Report) Director Gregg Williams purchased 1,587,301 shares of the company's stock in a transaction that occurred on Wednesday, April 15th. The stock was...

Vivani Medical (NASDAQ:VANI) Director Gregg Williams Acquires 1,587,301 Shares

Vivani Medical, Inc. (NASDAQ:VANI - Get Free Report) Director Gregg Williams purchased 1,587,301 shares of the firm's stock in a transaction on Wednesday, April 15th. The shares were purchased at an...

Vivani Medical, Inc. (NASDAQ:VANI) Sees Large Increase in Short Interest

Vivani Medical, Inc. (NASDAQ:VANI - Get Free Report) saw a significant growth in short interest in March. As of March 31st, there was short interest totaling 532,131 shares, a growth of 65.0% from the March 15th total of 322,575 shares. Currently, 1.2% of the company's stock are sold short. Based...

Vivani Medical (VANI) Upgraded to Buy: What Does It Mean for the Stock?

Vivani Medical (VANI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

HC Wainwright Lifts Earnings Estimates for Vivani Medical

Vivani Medical, Inc. (NASDAQ:VANI - Free Report) - Stock analysts at HC Wainwright increased their Q1 2026 EPS estimates for Vivani Medical in a research note issued to investors on Tuesday, March 31st. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings of ($0.08) per sh...

This account has been verified as an official VANI representative.

Verified Account

Vivani Medical

Vivani Medical, Inc. is a preclinical stage biopharmaceutical company, which engages in the business of developing miniaturized, subdermal implants utilizing proprietary NanoPortal technology to enable long-term, near constant-rate delivery of a broad range of medicines to treat chronic diseases. It operates under the Biopharm Division and Neuromodulation Division segments. The company was founded by Adam Mendelsohn on May 22, 2003 and is headquartered in Alameda, CA.

Vivani Medical Inc

Bullish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$1.12
Prev Close	$1.15
Open	$1.15
Dividend Yield	0.00%
50-Day Moving Average	$1.30
Beta	0.83
Avg. Volume	233,294.70
PE Ratio	-3.15

52-Week High	$1.92
52-Week Low	$0.9228
Market Capitalization	$101.03M
EPS (Annual)	-$0.4265
Price to Book	5.28
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

VANI Fundamentals